Physicochemical stability of durvalumab (Imfinzi®) concentrate for solution in original vials after first opening
Durvalumab (Imfinzi®), a PD-L1 monoclonal antibody (mAb) medication is available as concentrate (50 mg/mL) for solution for infusion. The summary of product characteristics provides information about the physicochemical stability of ready-to-administer durvalumab preparations (vehicle solution 0.9 %...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
De Gruyter
2023-07-01
|
| Series: | Pharmaceutical Technology in Hospital Pharmacy |
| Subjects: | |
| Online Access: | https://doi.org/10.1515/pthp-2023-0008 |